Cochlear's HY26 saw profit decline and steady dividends, as Nexa implant rollout supports second-half growth plans. The post ...

Cochlear implants have changed the lives of 29 residents of Holguin, who went from suffering from profound bilateral ...

Impeccable Cantonese cooking is on show at the Club Rivers restaurant.

Investors showed little affection for our healthcare heavyweights in February, cooling even on solid results. Maybe cheaper ...

Morgans has given its verdict on these shares this week. The post What is Morgans saying about Cochlear, Deep Yellow, and ...

Vancouver Canucks forward Conor Garland has a routine in the warmup skate with Tyler Myers’ son, Tristan Myers. Tristan had a traumatic birth, which led to him hav ...

Patients Implanted; Enrollment Completion Anticipated by End of March White Bear Lake, Minnesota–(Newsfile Corp. – February 17, 2026) – Envoy Medical® Inc. (NASDAQ: COCH) (“Envoy Medical” ...

The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have ...

Australian shares declined on Friday, dragged down by commodity and healthcare stocks, while hearing-implants maker Cochlear ...

Explore Cochlear's strategies for managing revenue and margins as it prepares to release its HY 2026 earnings.

Hearing device manufacturer Cochlear has suffered a 19 per cent sell-off after posting weaker-than-expected half-year earnings and trimming its guidance.

Earnings season has been brutal for these 3 healthcare sector giants. The post Buy, hold, sell: CSL, Pro Medicus, Cochlear shares appeared first on The Motley Fool Australia.